<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930916</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A00586-37</org_study_id>
    <nct_id>NCT01930916</nct_id>
  </id_info>
  <brief_title>Accuracy of a Portable International Normalized Ratio Monitor in Elderly Patients</brief_title>
  <acronym>AGINR</acronym>
  <official_title>Accuracy of a Portable International Normalized Ratio Monitor in a Population Aged 75 Years Old and Over</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral anticoagulants vitamin K antagonists (VKA) have been used for many years in the&#xD;
      treatment of thromboembolic disorders, which are among the most costly diseases in terms of&#xD;
      public health resources. According to the Agence française de sécurité sanitaire des produits&#xD;
      de santé (AFSSAPS), it was estimated at about 900,000 the number of patients treated with VKA&#xD;
      in 2008 (more than 1% of the French population). VKA are at the origin of many adverse&#xD;
      effects, given their narrow therapeutic window. They are the cause of the death of&#xD;
      approximately 5000 patients per year. The use of this therapy is a priority axis of&#xD;
      reflection for the Haute Autorité de Santé.&#xD;
&#xD;
      The interregion G4 (Nord Pas de Calais, Normandy, Picardy), with more than 9 million people,&#xD;
      is particularly affected by this problem.&#xD;
&#xD;
      University hospitals of our interregion, given their very substantial regional referral&#xD;
      activity, are actually involved in managing VKA adverse side effects.&#xD;
&#xD;
      Elderly population constitutes the majority of prescriptions. The main objective of this&#xD;
      study is to compare INR of people older than 75 years measured by traditional method with&#xD;
      those measured by capillary method with INRatio2 supply.&#xD;
&#xD;
      The secondary objective is to show that this measure is not affected by the presence or&#xD;
      absence of anti-phospholipid antibodies, probably very prevalent in the elderly, as well as&#xD;
      to test the variability of INR measurement between different hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adverse effects of oral anticoagulants (warfarin, fluindione mainly) are bleeding&#xD;
      complications and concern 13% of hospitalizations, approximately 17,000 admissions per year.&#xD;
      They constitute 12.3% of iatrogenic adverse effect according to the latest results of the&#xD;
      survey conducted by the haute autorité de santé (HAS). A study realized in 2000, with 2976&#xD;
      patients, shows that 28.8% of patients were outside of any therapeutic range (&lt;2 or&gt; 4.5). In&#xD;
      2003, a third of french biologists had no knowledge of the indication of VKA treatment of&#xD;
      patients at the INR measurement, and more than fifty percent in 2000. When the therapeutic&#xD;
      range was known, the value of the INR remained outside it in 30% of cases. The median time&#xD;
      between INR equilibration phase was 5 to 6 days, while the recommended time is 2 to 4 days. A&#xD;
      quarter of patients in phase equilibrium treatment did not have a measure of INR at least&#xD;
      once a month. Followed over a period of a year, patients spent 40% of the time with a value&#xD;
      of INR outside the therapeutic range, high-risk area of recurrent thrombosis or hemorrhage.&#xD;
      That is why they require regular monitoring of INR.&#xD;
&#xD;
      Currently, this monitoring is done through a blood sample analyzed by a laboratory according&#xD;
      to standard techniques.&#xD;
&#xD;
      The use of the INR measurement by capillary method provides a result in less than 3 minutes.&#xD;
      This also allows the development of different monitoring strategies. In the context of a&#xD;
      self-monitoring measure, the patient himself performs the test using the device and&#xD;
      therapeutic adjustment is made by the health care professional.&#xD;
&#xD;
      Data analysis by HAS showed that the use of a self-measurement device significantly improved&#xD;
      the time spent in the therapeutic range, reduced the risk of major bleeding and the accident&#xD;
      major thromboembolism.&#xD;
&#xD;
      The pathologies treated by VKA are more common in the elderly. They are also more vulnerable&#xD;
      to falls, overdoses of these treatments because their pharmacokinetics is amended by&#xD;
      polypharmacy, malnutrition, less protein binding. The relative risk of bleeding is&#xD;
      multiplicated by two beyond 70 years. Despite the emergence of new anticoagulants in the&#xD;
      prevention of complications of arrhythmia (this disorder affect nearly 10% of the population&#xD;
      aged over 80 years), VKA remains prevalent because these new drugs have renal elimination&#xD;
      that can not be monitored, and can not be dialysable, have no antidote and represent a daily&#xD;
      cost about 30 times the VKA.&#xD;
&#xD;
      The question of the use of devices for self-measurement of INR in the elderly is particularly&#xD;
      timely, because this population has never had, to our knowledge, a specific evaluation of&#xD;
      this technique.&#xD;
&#xD;
      Elderly population would derive the greatest benefit of this system because it will&#xD;
      significantly improve the time spend in the therapeutic range, and reduce the risk of&#xD;
      bleeding and thromboembolic events in reducing INR fluctuations.&#xD;
&#xD;
      We build a multicenter study whose main objective is to demonstrate the concordance of INR&#xD;
      measurement by the capillary way (INRatio2 ®, SAS ALERE, Jouy-en-Josas) with venous technical&#xD;
      reference. It concerns patients older than 75 years treated with VKA and hospitalized in&#xD;
      Internal Medicine, Geriatrics and Vascular Medicine in the fours university hospital of the&#xD;
      G4 region. The secondary objectives are to estimate the prevalence of antiphospholipid&#xD;
      antibodies (ranging from 12 to 55% depending on the study) and their influence on the&#xD;
      measurement of the INR by capillary method and the variability of the INR veinous measurement&#xD;
      in function of the hospital, with a centralized INR measurement which allow to compare. 150&#xD;
      patients is required to perform this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>INR by capillary method and INR by veinous punction</measure>
    <time_frame>24 hours</time_frame>
    <description>INR by the classical way (punction) and comparison with a capillary method tested here.&#xD;
INR by capillary method is done immediately after inclusion. INR by veinous punction is done on the 24 hours after the inclusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between International normalized ratio (INR) measured in a veinous blood punction and with a capillary method on the same patient and correlated to the level of phospholipid antibodies and lupus anti coagulant</measure>
    <time_frame>1 year</time_frame>
    <description>We want to know if the level of lupus and anti cardiolipin antibodies influence the value of INR measured by capillary method.&#xD;
lupus and anti cardiolipin antibodies tubes will be frozen after punction and analysed up to 1 year after.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Difference of INR measurement by veinous method between Caen laboratory and the local center laboratory.</measure>
    <time_frame>1 year</time_frame>
    <description>INR of a patient will be measured in two different center (Caen is the reference center).&#xD;
Blood sample will be frozen after punction and analysed up to 1 year after.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Blood Coagulation Disorders</condition>
  <condition>Blood Coagulation Disorder With Prolonged Bleeding Time</condition>
  <condition>Blood Coagulation Disorder With Prolonged Coagulation Time</condition>
  <arm_group>
    <arm_group_label>Not interventionnal</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>INR capillary measurement with INRatio 2 device antiphospholipid antibodies and lupus anticoagulant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>INR capillary measurement with INRatio 2 device</intervention_name>
    <description>INR capillary measurement with INRatio 2 device</description>
    <arm_group_label>Not interventionnal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>antiphospholipid antibodies and lupus anticoagulant</intervention_name>
    <description>Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.</description>
    <arm_group_label>Not interventionnal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 75 years&#xD;
&#xD;
          -  Recipient of the social security system&#xD;
&#xD;
          -  Patient receiving anti vitamin K treatment&#xD;
&#xD;
          -  Hospitalized in Internal Medicine, Geriatrics, Vascular Medicine&#xD;
&#xD;
          -  Having signed an informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to a digital sampling.&#xD;
&#xD;
          -  Conditions preventing the realization of INRatio2 ® test : Amputation of the&#xD;
             extremities, trophic disorders of the extremities.&#xD;
&#xD;
          -  Concomitant use of heparin.&#xD;
&#xD;
          -  Mental or physical illness which do not permit to consent to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Bienvenu, M.D,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier régional universitaire de Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Jacques Dutheil</last_name>
    <role>Study Director</role>
    <affiliation>Centre hospitalier régional universitaire de Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Auboire, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Centre hospitalier régional universitaire de Caen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boris Bienvenu, M.D, Ph.D</last_name>
    <phone>+33 (0)2 31 06 45 84</phone>
    <email>bienvenu-b@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier régional universitaire d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Antoinette Sevestre, M.D,Ph.D</last_name>
      <phone>+ 33 3 22 45 59 30</phone>
      <email>sevestre.marie-antoinette@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-antoinette Sevestre, M.D, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Jouanny, M.D,Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Francois Claisse, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier régional universitaire de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Bienvenu, M.D,Ph.D</last_name>
      <phone>+33 (0)2 31 06 45 84</phone>
      <email>bienvenu-b@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>boris bienvenu, M.D,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>laurent Auboire, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>brigitte le mauff, M.D,Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Descatoire, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier régional universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Lambert, M.D,Ph.D</last_name>
      <phone>+33 3 20 44 42 96</phone>
      <email>marc.lambert@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>marc lambert, M.D,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francois Puisieux, M.D,Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Boulanger, M.D,Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier régional universitaire de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ygal Benhamou, M.D</last_name>
      <email>ygal.benhamou@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Ygal Benhamou, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeanne Yvonne BORG, M.D,Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Chassagne, M.D,Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-02/synthese_inr_1437.pdf</url>
    <description>Background of french situation</description>
  </link>
  <link>
    <url>http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-02/rapport_inr_2009-02-09_17-42-19_375.pdf</url>
    <description>Background</description>
  </link>
  <reference>
    <citation>Manoussakis MN, Tzioufas AG, Silis MP, Pange PJ, Goudevenos J, Moutsopoulos HM. High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol. 1987 Sep;69(3):557-65.</citation>
    <PMID>3499270</PMID>
  </reference>
  <reference>
    <citation>Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001 Nov;86(5):516-21.</citation>
    <PMID>11602543</PMID>
  </reference>
  <reference>
    <citation>Bazzan M, Montaruli B, Vaccarino A, Fornari G, Saitta M, Prandoni P. Presence of low titre of antiphospholipid antibodies in cancer patients: a prospective study. Intern Emerg Med. 2009 Dec;4(6):491-5. doi: 10.1007/s11739-009-0316-6. Epub 2009 Sep 26.</citation>
    <PMID>19784751</PMID>
  </reference>
  <reference>
    <citation>Sène D, Piette JC, Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev. 2008 Feb;7(4):272-7. doi: 10.1016/j.autrev.2007.10.001. Epub 2007 Oct 23. Review.</citation>
    <PMID>18295729</PMID>
  </reference>
  <reference>
    <citation>Quéméneur T, Lambert M, Hachulla E, Dubucquoi S, Caron C, Fauchais AL, Devulder B, Hatron PY. Significance of persistent antiphospholipid antibodies in the elderly. J Rheumatol. 2006 Aug;33(8):1559-62.</citation>
    <PMID>16832847</PMID>
  </reference>
  <reference>
    <citation>Perry SL, Samsa GP, Ortel TL. Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies. Thromb Haemost. 2005 Dec;94(6):1196-202.</citation>
    <PMID>16411394</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>November 16, 2012</study_first_submitted>
  <study_first_submitted_qc>August 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2013</study_first_posted>
  <last_update_submitted>April 8, 2014</last_update_submitted>
  <last_update_submitted_qc>April 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prothrombin Time/instrumentation</keyword>
  <keyword>Prothrombin Time/utilization</keyword>
  <keyword>Blood Coagulation Disorders/blood</keyword>
  <keyword>Blood Coagulation Disorders/complications</keyword>
  <keyword>Blood Coagulation Disorders/diagnosis</keyword>
  <keyword>Prospective Studies</keyword>
  <keyword>Adult</keyword>
  <keyword>Reproducibility of Results</keyword>
  <keyword>Point-of-Care Systems/utilization</keyword>
  <keyword>Aged</keyword>
  <keyword>Elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Antiphospholipid</mesh_term>
    <mesh_term>Lupus Coagulation Inhibitor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

